drug · small molecule
ibrexafungerp citrate
Marketedupdated 5mo agoby $GSK GSK plc🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for vulvovaginal candidiasis and 1 investigational indication.
targets
1,3-beta-glucan synthase
all catalysts(4)
approval · 4
Jun 1, 2021
approval
BREXAFEMME (IBREXAFUNGERP CITRATE) — FDA approval
ibrexafungerp citrate
→
Jun 15, 2022
approval
BREXAFEMME (IBREXAFUNGERP CITRATE) — FDA approval
ibrexafungerp citrate
→
Nov 30, 2022
approval
BREXAFEMME (IBREXAFUNGERP CITRATE) — FDA approval
ibrexafungerp citrate
→
Nov 3, 2025
approval
BREXAFEMME (IBREXAFUNGERP CITRATE) — FDA approval
ibrexafungerp citrate
→
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 28, 2030
~3.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (5)
- Jun 10, 2039method-of-use (U-3508)US 11534433
- Jan 19, 2035compositionUS 10174074
- Jan 19, 2035method-of-use (U-3159)US 10370406
- Jan 19, 2035compositionUS 10927142
- Aug 28, 2030compositionUS 81880853.9y
FDA exclusivities (2)
- Jun 1, 2031GAINGAIN Antibiotic (5y)4.7y
- Jun 1, 2026NCENew Chemical Entity (5y)
News(1)
- Scynexis bags $214M BARDA contract for antifungal developmentThe Biomedical Advanced Research and Development Authority (BARDA) has awarded Scynexis a $214 million contract for the development of a treatment for invasive fungal infections.fiercebiotech · 1d ago
Data sources
last refreshed 53m ago
Found something off?
comments(0)
5-min edit window · permanent after that